Lantheus Holdings, Inc. (NASDAQ:LNTH) Stock Holdings Raised by MPM Bioimpact LLC

MPM Bioimpact LLC lifted its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 57.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 236,213 shares of the medical equipment provider's stock after acquiring an additional 86,031 shares during the quarter. Lantheus makes up 3.0% of MPM Bioimpact LLC's portfolio, making the stock its 8th biggest position. MPM Bioimpact LLC owned 0.34% of Lantheus worth $21,132,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Kestra Investment Management LLC bought a new position in shares of Lantheus during the fourth quarter valued at approximately $27,000. Summit Securities Group LLC bought a new position in shares of Lantheus during the fourth quarter valued at approximately $37,000. UMB Bank n.a. raised its holdings in shares of Lantheus by 31.5% during the fourth quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock valued at $50,000 after acquiring an additional 134 shares in the last quarter. Parkside Financial Bank & Trust raised its holdings in shares of Lantheus by 49.4% during the fourth quarter. Parkside Financial Bank & Trust now owns 847 shares of the medical equipment provider's stock valued at $76,000 after acquiring an additional 280 shares in the last quarter. Finally, 1620 Investment Advisors Inc. bought a new position in shares of Lantheus during the fourth quarter valued at approximately $125,000. Institutional investors own 99.06% of the company's stock.

Lantheus Price Performance

Shares of LNTH stock traded down $2.42 on Monday, hitting $78.83. 493,454 shares of the stock traded hands, compared to its average volume of 979,721. The firm has a market cap of $5.45 billion, a price-to-earnings ratio of 13.11 and a beta of 0.23. Lantheus Holdings, Inc. has a 52 week low of $75.00 and a 52 week high of $126.89. The firm has a 50 day simple moving average of $97.11 and a two-hundred day simple moving average of $93.08.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share for the quarter, missing analysts' consensus estimates of $1.64 by ($0.11). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The firm had revenue of $372.76 million for the quarter, compared to analysts' expectations of $377.37 million. During the same quarter last year, the firm posted $1.69 EPS. The firm's quarterly revenue was up .8% compared to the same quarter last year. Sell-side analysts forecast that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages recently commented on LNTH. Truist Financial decreased their target price on Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a report on Thursday, May 8th. StockNews.com upgraded Lantheus from a "hold" rating to a "buy" rating in a report on Thursday, May 8th. Finally, B. Riley decreased their price objective on Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a report on Friday, March 21st. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $132.67.

Insider Activity at Lantheus

In other Lantheus news, CFO Robert J. Jr. Marshall sold 10,000 shares of the business's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $100.52, for a total value of $1,005,200.00. Following the sale, the chief financial officer now owns 113,860 shares in the company, valued at $11,445,207.20. The trade was a 8.07% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Mary Anne Heino sold 53,107 shares of the company's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the sale, the director now owns 440,399 shares in the company, valued at $41,551,645.65. This represents a 10.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 63,109 shares of company stock worth $6,016,046. 1.50% of the stock is owned by corporate insiders.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.